期刊
JOURNAL OF RHEUMATOLOGY
卷 39, 期 10, 页码 2012-2020出版社
J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.120299
关键词
PEDIATRIC VASCULITIS; ANTINEUTROPRIL CYTOPLASMIC ANTIBODIES; SEVERITY; CYCLOPHOSPHAMIDE
类别
资金
- Vasculitis Foundation
- British Columbia Children's Hospital Foundation Telethon Grant
- Childhood Arthritis and Rheumatology Research Alliance (CARRA)
Objective. To determine whether adult disease severity subclassification systems for antineutrophil cytoplasmic antibody-associated vasculitis (AAV) are concordant with the decision to treat pediatric patients with cyclophosphamide (CYC). Methods. We applied the European Vasculitis Study (EUVAS) and Wegener's Granulomatosis Etanercept Trial (WGET) disease severity subclassification systems to pediatric patients with AAV in A Registry for Childhood Vasculitis (ARChiVe). Modifications were made to the EUVAS and WGET systems to enable their application to this cohort of children. Treatment was categorized into 2 groups, cyclophosphamide and no cyclophosphamide. Pearson's chi-square and Kendall's rank correlation coefficient statistical analyses were used to determine the relationship between disease severity subgroup and treatment at the time of diagnosis. Results. In total, 125 children with AAV were studied. Severity subgroup was associated with treatment group in both the EUVAS (chi-square 45.14, p < 0.001, Kendall's tau-b 0.601, p < 0.001) and WGET (chi-square 59.33, p < 0.001, Kendall's tau-b 0.689, p < 0.001) systems; however, 7 children classified by both systems as having less severe disease received CYC, and 6 children classified as having severe disease by both systems did not receive CYC. Conclusion. In this pediatric AAV cohort, the EUVAS and WGET adult severity subclassification systems had strong correlation with physician choice of treatment. However, a proportion of patients received treatment that was not concordant with their assigned severity subclass. (First Release Aug 1 2012; J Rheumatol 2012;39:2012-20; doi:10.3899/jrheum.120299
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据